levamlodipine
Trade name: Conjupri
Approved
Dec 19, 2019
Levalmodipine (S-amlodipine) is an active enantiomer of amlodipine, a calcium antagonist that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that S-amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. S-Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Enantiomerically pure S-amlodipine is marketed in some countries worldwide, while racemate, containing active S-enantiomer an inactive R-enantiomer is marketed in the USA and indicated for the treatment of hypertension and coronary artery disease. — NCATS
Clinical trial activity
14 trials · 23 clinical orgs · 1 marketing orgs
Earliest trial started Jan 1, 2006 (NCT00289406)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 3 Sponsor(trial)
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
- Dec 19, 2019
Shijiazhuang Pharma Group (CSPC) — Earliest FDA Approval
- Dec 19, 2019
Shijiazhuang Pharma Group (CSPC) — Marketing Organization
- Dec 19, 2019
Shijiazhuang Pharma Group (CSPC) — NDA Organization
Indications
Approved for
Mechanism of action
8233057 antagonist
Voltage-gated L-type calcium channel blocker
Binds dihydropyridine and nondihydropyridine binding sites.
Approval history
- approvedDec 19, 2019
Chemistry & pharmacology
SMILES
CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C2=CC=CC=C2Cl)C(=O)OC- Mol. weight
- 408.876 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaLevamlodipine ↗
- NCATS0P6NLP6806 ↗
- ChEMBLCHEMBL4594288 ↗
Also known as
- 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-3-ethoxy-carbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine
- l-amlodipine
- levamlodipine
- levamlodipine
- levamlodipine
- levamlodipine
- levamlodipine
- levamlodipine besylate
- levamlodipine besylate
- levamlodipine besylate
- levamlodipine malate
- levamlodipine malate
- levoamlodipine
- levoamlodipine
- levoamlodipine
- (s)-amlodipine
- s-amlodipine
- s-amlodipine
- s-amlodipine
- s-amlodipine gentisate
- s-amlodipine gentisate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06771245 | Phase 3 | Jan 24, 2025 | Shijiazhuang Pharma Group (CSPC) |
| NCT04411875 | Phase 1 | Nov 13, 2018 | Qingdao University |
| NCT03657550 | Phase 1 | May 31, 2018 | Yiling Pharmaceutical Inc. |
| NCT02358824 | Phase 1 | Feb 1, 2015 | Chong Kun Dang Pharmaceutical, Kyungpook University |
| NCT02250833 | Phase 1 | Sep 1, 2014 | Chong Kun Dang Pharmaceutical, Kyungpook University |
| NCT01983735 | Phase 3 | Jan 1, 2014 | Chong Kun Dang Pharmaceutical |
| NCT03038451 | Phase 4 | Mar 20, 2013 | NeuTec Pharma |
| NCT01634295 | Phase 3 | Jul 1, 2012 | Catholic University of Korea, Chong Kun Dang Pharmaceutical, Dong-A University, Ewha Womans University, Gachon University, Hallym University, Konyang University, Korea University, Kyung Hee University, Seoul National University, Yonsei University |
| NCT01501253 | Phase 3 | Aug 1, 2011 | Catholic University of Korea, Chong Kun Dang Pharmaceutical |
| NCT01356043 | Phase 1 | May 1, 2011 | Chong Kun Dang Pharmaceutical, University of Ulsan |
| NCT01128322 | Phase 2 | Jul 1, 2010 | Chong Kun Dang Pharmaceutical |
| NCT04740840 | Phase 2/Phase 3 (Phase 3) | May 1, 2010 | North Sichuan Medical University, People's Liberation Army of China |
| NCT01131546 | Phase 4 | Dec 1, 2009 | Fudan University, Peking University, Simcere Pharmaceutical Co., Ltd |
| NCT00289406 | Phase 3 | Jan 1, 2006 | SK Chemicals |
Organizations
Research & Development (23)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chong Kun Dang Pharmaceutical | For profit | 7 | 7 | 3 | 2010 |
| Catholic University of Korea | Academic/Hospital | 2 | 0 | 1 | 2011 |
| Kyungpook University | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Dong-A University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Ewha Womans University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Gachon University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Hallym University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Konyang University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Korea University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Kyung Hee University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| NeuTec Pharma | For profit | 1 | 1 | 1 | 2013 |
| North Sichuan Medical University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2010 |
| Qingdao University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Shijiazhuang Pharma Group (CSPC) | For profit | 1 | 1 | 1 | 2025 |
| Simcere Pharmaceutical Co., Ltd | For profit | 1 | 1 | 1 | 2009 |
| SK Chemicals | For profit | 1 | 1 | 1 | 2006 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Shijiazhuang Pharma Group (CSPC) | For profit | MKTG | Dec 19, 2019 |
| Shijiazhuang Pharma Group (CSPC) | For profit | SYN | Dec 19, 2019 |
| Shijiazhuang Pharma Group (CSPC) | For profit | NDA | Dec 19, 2019 |